Physician profile
Michael B Pryor
NPI 1699711317
$5,098.44
in general payments reported to CMS, 2019-2025
39 companies · $510 in 2025
The $510 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $836 · 2021: $1,261 · 2022: $719 · 2023: $714 · 2024: $586 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,315.40 | 2019-2024 | Speedicath, Titan |
| Astellas Pharma US INC | $593.99 | 2019-2025 | Myrbetriq, Xtandi |
| Boston Scientific Corporation | $592.20 | 2019-2025 | Ams 700, Lithovue, Watchman Flx |
| Abbvie INC. | $548.99 | 2019-2025 | |
| Antares Pharma, INC. | $416.83 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Procept Biorobotics Corporation | $263.94 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Cipla USA INC. | $168.41 | 2021 | |
| Pfizer INC. | $125.63 | 2019-2022 | |
| Janssen Biotech, INC. | $105.36 | 2019-2023 | Erleada |
| Merck Sharp & Dohme LLC | $92.81 | 2020-2024 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $73.53 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $67.18 | 2023-2024 | Gemtesa |
| Tolmar Pharmaceuticals, INC. | $67.11 | 2019-2021 | |
| Urovant Sciences INC | $60.74 | 2021-2022 | |
| Olympus America INC. | $56.32 | 2022-2025 | Itind System |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $55.18 | 2021-2024 | |
| Medtronic, INC. | $51.21 | 2025 | Interstim |
| Smith+Nephew, INC. | $40.97 | 2020-2021 | |
| Urogen Pharma, INC. | $37.06 | 2022-2023 | Jelmyto |
| Laborie Medical Technologies Corp. | $32.34 | 2022-2025 | |
| Myovant Sciences INC. | $29.97 | 2021 | |
| Baudax Bio INC. | $26.27 | 2020 | |
| Axonics, INC. | $22.18 | 2024 | Axonics, Bulkamid |
| Astrazeneca Pharmaceuticals LP | $21.65 | 2022 | |
| Baxter Healthcare | $18.97 | 2022 | |
| Amgen INC. | $18.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.87 | 2022 | |
| Genzyme Corporation | $17.55 | 2022 | |
| Dendreon Pharmaceuticals LLC | $16.81 | 2022 | |
| Clarus Therapeutics INC. | $16.63 | 2021 | |
| Travere Therapeutics, INC. | $16.41 | 2019 | |
| Metuchen Pharmaceuticals | $16.18 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.14 | 2024 | Adstiladrin |
| Aytu Biopharma, INC. | $14.99 | 2020 | |
| Tolmar, INC. | $14.41 | 2024 | |
| Angiodynamics, INC. | $13.95 | 2025 | Nanoknife |
| Blue Earth Diagnostics | $13.81 | 2023 | |
| Endo Pharmaceuticals INC. | $12.16 | 2020 | |
| Ambu INC. | $9.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pryor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.